Gilead Follows Up Wall St. Hot Streak with Big Money Alliances
An enviable cash position gives Gilead the luxury of making agreements like licensing exclusive ex-US rights to Vistide to Pharmacia & Upjohn. They also entered a broader deal with Hoffmann-La Roche surrounding its neuraminidase inhibitor program for influenza treatment.
You may also be interested in...
Zydus Cadila expects domestic sales to improve and the US generics business to grow in “mid to high” single digits during FY21 after both saw a coronavirus-related hit in Q1. Meanwhile, approvals for a few biologics are expected, its COVID-19 vaccine candidate has just entered Phase II studies and remdesivir launch looms.
At-home nail and hair care and e-commerce were bright spots in a numbing second quarter for Revlon, which was hit hard by mass retail and salon channel closures at a time of ongoing transformation.
Agency has created a centralized team to help review divisions with virtual advisory committee preparations and is trying to notify sponsors earlier in the review process about the need for a panel; sponsors cite importance of having a back channel of communications so team members can communicate with each other while an AdComm is underway.